iMDx to Showcase GraftAssure, Present Head-to-Head Data and Grant Awards at Boston Conference
IMDX•iMDx will highlight its GraftAssure transplant rejection assay at the American Transplant Congress in Boston from June 20-24 and announce recipients of a grant to evaluate the economics of in-house organ-rejection testing. The company will present favorable head-to-head data and pursue FDA authorization for its droplet digital PCR test kit.
1. American Transplant Congress Participation
iMDx will demonstrate its GraftAssure technology across multiple sessions at the American Transplant Congress in Boston from June 20 to 24. The company will outline three paradigm shifts in transplant monitoring, including local dd-cfDNA testing within hospital labs, expanded clinical applications, and comprehensive rule-in decision support.
2. Grant Sponsorship and Economic Study
iMDx and the American Society of Transplant Surgeons will award grants to researchers examining the economic impact of running organ-rejection assays in-house rather than relying on centralized reference labs. The study aims to quantify cost savings and turnaround time improvements for local transplant center laboratories.
3. Head-to-Head Data and FDA Authorization
On June 23, a third-party poster will present new head-to-head comparisons of GraftAssureIQ against a leading commercial assay, reinforcing prior favorable results. Concurrently, iMDx is seeking FDA marketing authorization for its GraftAssureDx droplet digital PCR kit to enable hospitals to perform local dd-cfDNA testing.
